{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["11(13)"],"submitter":["Chen S"],"pubmed_abstract":["Background Patients with arrhythmogenic right ventricular cardiomyopathy are at risk for life-threatening ventricular tachyarrhythmias, but progressive heart failure (HF) may occur in later stages of disease. This study aimed to characterize potential risk predictors and develop a model for individualized assessment of adverse HF outcomes in arrhythmogenic right ventricular cardiomyopathy. Methods and Results Longitudinal and observational cohorts with 290 patients with arrhythmogenic right ventricular cardiomyopathy from the Fuwai Hospital in Beijing, China, and 99 patients from the University Heart Center in Zurich, Switzerland, with follow-up data were studied. The primary end point of the study was heart transplantation or death attributable to HF. The model was developed by Cox regres"],"journal":["Journal of the American Heart Association"],"pagination":["e024634"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9333366"],"repository":["biostudies-literature"],"pubmed_title":["Novel Risk Prediction Model to Determine Adverse Heart Failure Outcomes in Arrhythmogenic Right Ventricular Cardiomyopathy."],"pmcid":["PMC9333366"],"pubmed_authors":["Hu S","Gasperetti A","Chen K","Brunckhorst C","Saguner AM","Chen L","Song J","Tang H","Li X","Duru F","Akdis D","Guo G","Chen S","Rao M"],"additional_accession":[]},"is_claimable":false,"name":"Novel Risk Prediction Model to Determine Adverse Heart Failure Outcomes in Arrhythmogenic Right Ventricular Cardiomyopathy.","description":"Background Patients with arrhythmogenic right ventricular cardiomyopathy are at risk for life-threatening ventricular tachyarrhythmias, but progressive heart failure (HF) may occur in later stages of disease. This study aimed to characterize potential risk predictors and develop a model for individualized assessment of adverse HF outcomes in arrhythmogenic right ventricular cardiomyopathy. Methods and Results Longitudinal and observational cohorts with 290 patients with arrhythmogenic right ventricular cardiomyopathy from the Fuwai Hospital in Beijing, China, and 99 patients from the University Heart Center in Zurich, Switzerland, with follow-up data were studied. The primary end point of the study was heart transplantation or death attributable to HF. The model was developed by Cox regres","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022 Jul","modification":"2026-03-27T17:24:41.725Z","creation":"2025-04-07T02:20:25.878Z"},"accession":"S-EPMC9333366","cross_references":{"pubmed":["35766284"],"doi":["10.1161/JAHA.121.024634"]}}